Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.
/ 237 items
#XY Event-Driven Stocks↓
FDA Clears Gain Therapeutics’ GT-02287 for Phase 2 Parkinson’s Trials
Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.
Edwards’ Ecliptis Wins FDA Clearance, Challenges AtriCure in Surgical LAA Market
Edwards got FDA OK for heart clip; it enters a market led by AtriCure, adding competition but not changing the outlook much.
Palisade Bio Stock Surges on Positive FDA Clearance for Next-Gen IBD Therapy
The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.
Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued
Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.
Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares
Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.